FibroGen, Inc (FGEN)
FGEN moved a median of -0.50% 30 minutes after news, and +0.06% by the close. How FGEN actually reacts to news — the realized, point-in-time move the market made, measured across 220 labeled events over the last three years with zero look-ahead.
FGEN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 186 |
| 30-min | -0.50% | 45% | 188 |
| 60-min | -0.04% | 47% | 188 |
| to close | +0.06% | 50% | 184 |
| Middle 50% of FGEN reactions | -3.46% to +2.27% |
|---|---|
| Median reaction (30-min) | -0.50% |
| Measured reactions | 220 |
Half of all FibroGen, Inc news events land between -3.46% and +2.27% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FGEN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 38 | +1.43% | 63% | +0.54% |
| Rating reiterations | 13 | +0.62% | 62% | -3.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how FGEN ranks against every other measured name →
That’s how FGEN usually reacts — get an email when it moves on news →Email me when FGEN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FGEN's baseline. Nothing else.
Recent FGEN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K KYNTRA BIO, INC. For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q KYNTRA BIO, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q KYNTRA BIO, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS KYNTRA BIO, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A KYNTRA BIO, INC. For: Jun 12 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form DEFA14A KYNTRA BIO, INC. | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-K KYNTRA BIO, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K KYNTRA BIO, INC. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 | Press release | GlobeNewswire | — | — | |
| FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum | Press release | GlobeNewswire | +0.43% | +5.20% | |
| Form 8-K FIBROGEN INC For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration | Press release | GlobeNewswire | +2.77% | +15.94% | |
| FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit | Press release | GlobeNewswire | +0.00% | +0.12% | |
| FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -9.72% | |
| Form 10-Q FIBROGEN INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -9.72% | |
| Form 8-K FIBROGEN INC For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -9.72% | |
| Form 8-K FIBROGEN INC For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +0.27% | |
| FibroGen to Report Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | +0.00% | |
| FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer | Press release | GlobeNewswire | -4.33% | +1.23% | |
| Form 8-K FIBROGEN INC For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -0.39% | -4.37% | |
| FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million | Press release | GlobeNewswire | -6.18% | +1.75% | |
| Form 8-K FIBROGEN INC For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -6.18% | +1.75% | |
| FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.28% | +5.90% | |
| FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation | Press release | GlobeNewswire | -0.50% | +13.80% | |
| Form 8-K FIBROGEN INC For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | +13.80% | |
| FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +6.67% | — | |
| Form 10-Q FIBROGEN INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.67% | — | |
| Form 8-K FIBROGEN INC For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +6.67% | — | |
| FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes | Press release | GlobeNewswire | +1.88% | +10.59% | |
| FibroGen to Report Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.87% | -1.29% | |
| Form 8-K FIBROGEN INC For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -4.06% | |
| Form 8-K FIBROGEN INC For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +1.85% | -1.44% | |
| FibroGen Announces 1-for-25 Reverse Stock Split | Press release | GlobeNewswire | -4.83% | -7.60% | |
| Form 8-K FIBROGEN INC For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -4.83% | -7.60% | |
| FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors | Press release | GlobeNewswire | -0.80% | -4.74% | |
| Form 8-K FIBROGEN INC For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -4.74% | |
| FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -6.25% | -6.47% | |
| Form 10-Q FIBROGEN INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.25% | -6.47% | |
| Form 8-K FIBROGEN INC For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -6.25% | -6.47% | |
| FibroGen to Report First Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.00% | -6.07% | |
| Form ARS FIBROGEN INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +5.68% | |
| Form DEF 14A FIBROGEN INC For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +5.68% | |
| Form DEFA14A FIBROGEN INC | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +5.68% | |
| Form PRE 14A FIBROGEN INC For: Jun 04 | SEC filing · Form PRE | SEC EDGAR | -3.01% | -4.11% | |
| Form 8-K FIBROGEN INC For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -6.67% | +1.15% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FGEN section they belong to.
Where else FGEN is measured.
FGEN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OASMIA PHARMACEUTICALS AB AMERICAN DEPOSITARY SHARE (OASM) | 223 | 0.00% | 35% |
| Atossa Therapeutics, Inc. (ATOS) | 222 | -0.02% | 48% |
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is FibroGen, Inc's median reaction calculated?
Every labeled FGEN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 220 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of FGEN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FGEN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.